MedPath

se of Shenhuang Paste on Shenque Point Improves Chemotherapy Induced Gastrointestinal Toxicity in breast Cancer: a Randomized Controlled Trial.

Phase 1
Conditions
Breast Cancer
Registration Number
ITMCTR2000003442
Lead Sponsor
Zhejiang Chinese Medical University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
Female
Target Recruitment
Not specified
Inclusion Criteria

1. Patients aged 40-60 years, KPS score >= 60 points, WBC >= 4.0 * 10^9L-1 before treatment, normal liver and renal function, expected survival > 3 months;
2. All were pathologically confirmed breast cancer patients who met the CLINICAL practice guidelines for NCCN breast cancer (2018.v1) after modified radical mastectomy and received chemotherapy with AC regimen (adriamycin + cyclophosphamide) or TAC regimen (docetaxel + adriamycin + cyclophosphamide) for the first time.
3. It conforms to the provisions of Standard of Curative Effect of Diagnosis of Diseases and Syndromes of Traditional Chinese Medicine and Guiding Principles for Clinical Research of New Chinese Medicines;
4. All the selected patients have signed informed consent and are willing to accept the treatment of this program.

Exclusion Criteria

1. Other complications and liver and kidney dysfunction;
2. patients receiving other traditional Chinese medicine intervention (such as taking traditional Chinese medicine, traditional Chinese medicine application, etc.);

Study & Design

Study Type
Interventional study
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Condition of defecation;
Secondary Outcome Measures
NameTimeMethod
Analysis of fecal flora and metabolites;hemanalysis;
© Copyright 2025. All Rights Reserved by MedPath